Ethan Lipkind - Complete Healthcare Management Releases Study on ViiV Healthcare's Dolutegravir Patent

from web site

CHM has actually championed and supported improved access to healthcare and minimized expenses with a specific focus on those most susceptible. CHM produced a non-profit rural health system to assist ensure ongoing access for health care to 10s of thousands of clients, and, more recently, assisted develop a Medicare Advantage strategy which takes care of a disproportionately underserved population. Now, CHM is focused on drug store spend. CHM thinks it can assist to manage runaway pharmaceutical expenses by trying to shed light on those patents supporting really costly drugs which may be excessively broad or have actually been artificially extended beyond their original life times. Among the opportunities that they have actually selected to follow is to present their findings to the public, either through the filing of public court documents or by releasing the data straight to other interested third parties, in order to help get rid of flawed patents.

IPR has established an extensive and multifaceted procedure for identifying pharmaceutical patent filings that have taken advantage of the patent system. The main patent for dolutegravir was submitted in April of 2006 and is based upon innovation centered around inhibition of HIV integrase, an enzyme necessary for HIV infections. According to Dr. R.L. Smith of IPR, "" At the time of the filing, lots of compounds were known that inhibited HIV integrase. Not just were a number of HIV integrase inhibitors already developed, however lots of also had the very same or similar structural components as ViiV'' s dolutegravir. We think that the substance that was eventually approved as dolutegravir was really already evident in the prior art when the '' 385 was filed. We have provided our best arguments in this report."

" CHM President ethan lipkind stated, "" We hope that other pharmaceutical companies or interested celebrations will be able to utilize this info to possibly produce cheaper generic variations of this drug and to reduce the total cost of HIV treatment for our consumers and patients."